CSPC Pharmaceutical Group (HK:1093) has released an update. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments ...

CSPC Pharmaceutical Group has announced that its new product, SYS6041, an antibody-drug conjugate, has received clinical trial approval from China’s National Medical Products Administration.

Overview: CSPC Pharmaceutical Group Limited is an investment holding company involved in the research, development, manufacture, and sale of pharmaceutical products across China and ...

Overview: CSPC Pharmaceutical Group Limited is an investment holding company involved in the research, development, manufacture, and sale of pharmaceutical products across China and internationally, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

China National Offshore Oil Corporation (CNOOC) and Shell plc's joint venture, CNOOC and Shell Petrochemicals Company Limited (CSPC), announced Wednesday they would invest in the Huizhou Phase III ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceutical.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...